EXEL vs SNY: fair value comparison
Exelixis, Inc. and Sanofi · Updated 2026-09-06
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, SNY currently sits closer to the top of our discount ranking. EXEL carries the stronger quality grade.
| EXEL | SNY | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $55.06 | $42.95 |
| 12-month range | $38.06–$55.06 | $41.63–$47.40 |
| Sector rank | #46 of 113 Healthcare | #43 of 113 Healthcare |
| Quality grade | A | B |
| Leverage | Low | Low |
| Margin trend | Stable | Expanding |
| Revenue growth | Strong | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | Downtrend |
| DCF cross-check | Fairly Valued | Overvalued |
| 52-week position | The top quarter | The bottom quarter |
Full single-stock breakdowns: EXEL fair value analysis · SNY fair value analysis